XML 50 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Equity (USD $)
Total
Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Retained Earnings [Member]
Parent [Member]
Noncontrolling Interest [Member]
Beginning Balance at Dec. 31, 2009 $ 57,832,377 $ 100 $ 37,193 $ 95,709,491 $ (56,504) $ (71,776,951) $ 23,913,329 $ 33,919,048
Beginning Balance (in shares) at Dec. 31, 2009   10,000 37,193,491          
Net income (loss) (19,397,016)         (23,305,706) (23,305,706) 3,908,690
Foreign currency translation 2,835,570       2,835,570   2,835,570  
Exercise of stock options 140,100   90 140,010     140,100  
Exercise of stock options (in shares)     90,000          
Exercise of warrants 2,961,750   2,025 2,959,725     2,961,750  
Exercise of warrants (in shares)     2,025,000          
Share-based compensation 7,564,993   350 7,564,643     7,564,993  
Share-based compensation (in shares)     349,517          
Proceeds from issuance of common stock 21,425,538   15,327 21,410,211     21,425,538  
Proceeds from issuance of common stock (in shares)     15,326,998          
Conversion of Series C Preferred 13,720,048   9,086 13,710,962     13,720,048  
Conversion of Series C Preferred (in shares)     9,086,124          
Shares issued for charitable contribution 298,500   150 298,350     298,500  
Shares issued for charitable contribution (in shares)     150,000          
Receipt of treasury shares (656,278)   (408) (655,870)     (656,278)  
Dividends on Series C Preferred (153,469)         (153,469) (153,469)  
Dividends on Series E Preferred (84,494)         (84,494) (84,494)  
Ending Balance at Dec. 31, 2010 86,487,619 100 63,813 141,137,522 2,779,066 (95,320,620) 48,659,881 37,827,738
Ending Balance (in shares) at Dec. 31, 2010   10,000 64,221,130          
Net income (loss) (56,582,857)         (47,134,469) (47,134,469) (9,448,388)
Foreign currency translation 2,596,987       1,373,277   1,373,277 1,223,710
Exercise of stock options 7,100   5 7,095     7,100  
Exercise of stock options (in shares)     5,000          
Share-based compensation 10,266,023   3,824 10,262,199     10,266,023  
Share-based compensation (in shares)     3,824,018          
Proceeds from issuance of common stock 21,152,682   19,678 21,133,004     21,152,682  
Proceeds from issuance of common stock (in shares)     19,678,224          
Shares issued for charitable contribution 607,363   408 606,955     607,363  
Repayment of Series E Preferred Principaland Dividends 3,620,300   5,158 4,254,907   (639,765) 3,620,300  
Repayment of Series E Preferred Principaland Dividends (in shares)     5,157,732          
Dividends to related party (11,726,099)             (11,726,099)
Technology contributed to Athelosby Non-Controlling Interes 1,150,000     920,000     920,000 230,000
Stock Issued During Period Value PCT Merger 17,200,000   10,600 17,189,400     17,200,000  
Stock Issued During Period Shares PCT Merger     10,600,000          
Stock Issued During Period Value Amorcyte Merger 5,353,400   5,844 5,347,556     5,353,400  
Stock Issued During Period Shares Amorcyte Merger     5,843,483          
Ending Balance at Dec. 31, 2011 $ 80,132,518 $ 100 $ 109,330 $ 200,858,638 $ 4,152,343 $ (143,094,854) $ 62,025,557 $ 18,106,961
Ending Balance (in shares) at Dec. 31, 2011   10,000 109,329,587